10 results
In this study we would like to study the effects of the selective angiotensin II antagonist Telmisartan on inflammation and cell/matrix homeostasis in the human aneurysm aortic wall.
The aim of this study is to investigate if telmisartan reduces AAA growth
A better understanding on the individual response to different albuminuria lowering drugs and a better understanding why these drugs, of which some are developed for another indication, may help to tailor optimal therapy. Therefore in this study…
Investigate the activity and safety of amrubicin alone versus amrubicin incombination with cisplatin versus standard treatment for extensive disease(ED) small-cell lung cancer in the first line setting.
The primary objective is the Objective tumor response rate (RECIST). Secondary objectives are: duration of overall response, time to tumor progression (TTP), progression free survival (PFS), overall survival, toxicity profile, incidence of…
A better understanding on the individual response to different albuminuria lowering drugs and a better understanding why these drugs, of which some are developed for another indication, may help to tailor optimal therapy. Therefore in this study…
Primary objectives:* To assess telmisartan target (i.e. receptor) specific binding in vivo* To assess receptor occupancy of telmisartan in vivo* To determine optimal scanning time in vivoSecondary objective:* To explore the effect of telmisartan on…
The primary objective is to estimate the average relative change from baseline in tumoruptake of [89Zr]Zr-BI 765063 (arm A) or [89Zr]Zr-BI 770371 (arm B) upon treatment with BI 765063 (arm A) or BI 770371 (arm B).
Objective: To assess whether angiotensin receptor blocker (ARB) use is beneficial in the early phase of the disease, to prevent lung oedema and damage in high risk patients with a proven COVID-19 infection.
To investigate the maximum tolerated dose (MTD) of BI 907828 in combination with ezabenlimab based on dose limiting toxicities (DLT) during the first treatment cycle and the recommended dose for expansion (RDE), safety and tolerability,…